PDE5A and melanoma: Given the importance of the question, and continuing uncertainty over a causal link, we aimed to examine the association between PDE5 inhibitors used for ED and the risk of incident melanoma in a large cohort of men using data from UK primary care, and to assess the causality of any observed increase in risk.